Introduction and goals
It is well recognized that replacing a hydrogen atom by a fluorine atom in a chemical entity can bring significant changes in its chemical and biochemical behaviour. Fluorine, due to its strong electron withdrawing effect (with reduced steric requirements) can have noticeable consequences on the electron distribution and subsequently on the acidity or basicity of the neighbouring group thereby changing the overall reactivity and stability of the molecule.
These impacts of fluorine atoms in biologically relevant molecules, especially in amino acids, can be advantageously exploited to lead to potent therapeutic agents through proper understanding of some biochemical properties such as:
-identification of binding sites with naturally occurring macromolecules such as enzymes, receptors, etc . . . -increasing resistance to metabolic transformation due to the strong carbon-fluorine bond. -investigation of recognition properties, mechanism and structure of enzymes through modification of the chemical reactivity with the use of fluorinated compounds as biological tracers and as mechanistic probes.
Introduction of fluorine atom at the C-4 position of glutamic acid has been realized in the screening of modulators for folate poly-γ-glutamate biosynthesis and to study the role of analogous derivatives of antifolates such as methotrexate (MTX) in the cytotoxic action of these drugs. In one of the crucial steps, the γ-carboxyl group of the C-terminal glutamate is activated by the enzyme prior to peptide coupling. Therefore, introducing one or more fluorine atoms in the α position with respect to the γ-carboxyl side chain could interfere with such biological processes (Hart et al., 1996; . As a second illustration, enantiomerically pure 4-fluoroglutamic acids were employed for investigating the mechanism of the vitamin K-dependent carboxylation of glutamic acid residues present in several proteins (Dubois et al., 1983) . Glutamine, the most abundant amino acid in the body, was originally classified as a "non-essential" amino acid. However, it is now considered as "conditionally essential" particularly after clinical trauma such as major surgery or burns (Castell and Newsholme, 2001) . It was established in the early 1980s that glutamine is an important fuel for some key cells of the immune system (Ardawi and Newsholme, 1983) .
In living cells, glutamic acid and glutamine are the main storage forms of nitrogen for the synthesis of macromolecules. While glutamate is able to deliver its α-amino group by transamination, labilisation by amide bond cleavage of glutamine δ nitrogen requires intervention of the catalytic machinery of glutamine-dependant amidotransferases (Gn-AT). Glucosamine-6-phosphate synthase, one of the Gn-AT, is involved in the biosynthesis of D-glucosamine 6-phosphate. The considerable involvement of D-glucosamine 6-phosphate synthase in a number of biological processes such as the biosynthesis of bacterial peptidoglycane or fungal cell wall and its potential as a therapeutic target in type-2 diabetes, requires the precise understanding of its mechanism at the molecular level (Massière and Badet-Denisot, 1998; Teplyakov et al., 2002) . It was hypothesised that fluorinated analogues of glutamine, particularly with fluorine in the α-position to the amide group, might interfere with the normal nitrogen transfer processes providing the basis for possible therapeutic agents. Several reviews dealing with the synthetic aspects of different classes of fluorinated amino acids have emerged in the area of fluorine chemistry. "Synthesis of γ-fluoro-α-amino acids" (Haufe and Kroger, 1996) , "Syntheses of fluorinated amino acids: from the classical to the modern concept" (Tolman, 1996) and "Synthesis of fluorinated amino acids" (Sutherland and Willis, 2000) are among the most recent ones. Kukhar and Soloshonok (Kukhar and Soloshonok, 1995) have comprehensively reviewed the syntheses and properties of fluorinated amino acids. Welch and Hudlicky have surveyed the general fluorination methodologies to account for the increasing interest of biochemists in fluoro compounds, reflected by an increasing number of relevant publications, particularly at the interface of fluorine/bioorganic chemistry (Welch, 1991; Hudlicky, 1992) . Although these reviews discuss in depth the chemistry of different classes of fluorinated compounds, there has not been much emphasis on the synthetic aspects of γ-fluorinated glutamic acid and glutamine (Fig. 1) . The present review discusses the syntheses of γ-fluorinated glutamines and glutamic acids described to date, with particular emphasis on asymmetric pathways and strategies of resolution of stereoisomers leading to γ-fluorinated compounds in diastereo-and enantiomerically enriched forms.
Syntheses of 4-fluoroglutamic acid and 4-fluoroglutamine 2
The presence of two stereocentres in 4-fluoroglutamic acid 1 and 4-fluoroglutamine 2 implies that they exist as two diastereomeric pairs of enantiomers as depicted in Fig 2. 
4-Fluoroglutamic acid 1
Several methods for the preparation of 4-fluoroglutamic acid 1 in racemic and enantiomerically pure form have been described in the literature. Historically, it is the first synthesis of any monofluorinated aliphatic amino acid. Ethyl α-fluoro acrylate 5 was subjected to Michael addition with diethyl acetamidomalonate 6 to yield ethyl α-carboethoxy-α-acetamido-γ-fluoroglutarate 7, which on acid hydrolysis followed by neutralisation with silver oxide gave 4-fluoroglutamic acid 1 in 31% overall yield based on 5 (Hudlicky, 1960; 1961) . The limitation of the approach was however the poor accessibility to the Michael acceptor 5 which was obtained in a poor 10% yield by a two-step procedure starting from ethyl α,α, -tribromopropionate 3. Upon fluorination with mercurous fluoride and iodine, 3 yielded ethyl α, -dibromo-α-fluoropropionate 4, which on subsequent dehalogenation with zinc gave ethyl α-fluoroacrylate 5 (Scheme 1).
4-Fluoroglutamic acid 1 was found to slightly inhibit the growth of Mycobacterium tuberculosis at a concentration of 50µg/mL over one week incubation.
Tolman and Veres improved the synthesis of 1 by using 3,3,3Ј,3Ј-tetramethyl-1,1Ј-spirobiindane-5,6,5Ј,6Ј-tetrol as a stabilizer for the Michael acceptor 5. With this additive, which is more stable in alkaline medium than hydroquinone, the yield of the Michael adduct 7 was enhanced by 21% (Tolman and Veres, 1967) .
Later on, the same authors optimised both the preparation and the reaction of the Michael acceptor to prepare 4-fluoroglutamic acid 1 on multigram scale. Ethyl 2-fluoroacrylate 5 of high purity was first prepared in quantitative yield by vacuum distillation of a mixture of potassium phthalimide and ethyl 2 -fluoro -3 -(4Ј -toluenesulphonyloxy)propionate (Tolman and Spronglova, 1983; Tolman and Veres, 1964) . Freshly prepared ethyl 2-fluoroacrylate 5 was then immediately subjected to Michael addition with diethyl acetamidomalonate 6 to afford the adduct 7 in 80-88% yield. Acid hydrolysis followed by neutralisation with pyridine and addition of ethanol gave crystalline 4-fluoroglutamic acid 1 in yields as high as 80% (Tolman, 1993 (Hudlicky, 1960 and 1961) . Diethyl fluoromalonate 10 was added to ethyl α-acetamidoacrylate 11 to yield diethyl α-acetamido-αЈ-carboethoxy-αЈ-fluoroglutarate 12 in good yield along with a small amount of 3,5-dicarboethoxy-3-fluoro-2-pyrrolidone, due to ring closure. The mixture was subjected to acid hydrolysis then neutralized with silver oxide to give 4-fluoroglutamic acid 1 in 56% overall yield based on diethyl fluoromalonate 10 (Buchanan et al., 1962) (Scheme 2). The key Michael donor, diethyl fluoromalonate 10 was prepared from ethyl fluoroacetate 8 and ethyl chloroformate 9 in 24% yield.
c) Fluorination
Perchloryl fluoride (ClO 3 F) and 2-chloro-1,1,2-trifluorotriethylamine (CTT) have been used as the electrophilic and nucleophilic fluorinating agents respectively for the preparation of 4-fluoroglutamic acid 1.
• Using perchloryl fluoride: Alekseeva et al. developed a novel and concise approach to synthesis of 4-fluoroglutamic acid 1 using electrophilic fluorination of the appropriately substituted tetraester 13 with perchloryl fluoride (ClO 3 F). The starting substance, tetraethyl 1-acetamido-1,1,3,3 propanetetracarboxylate 13 was obtained by condensation of malonic ester with paraformaldehyde and diethyl acetamidomalonate using a known literature procedure (Kaneko et al., 1962) . The treatment of the sodium salt of 13 with perchloryl fluoride (ClO 3 F) gave tetraethyl 1-acetamido-3-fluoro-1,1,3,3-propanetetracarboxylate 14 in 70-75% yield. Following acid hydrolysis and decarboxylation, 14 afforded 4-fluoroglutamic acid hydrochloride, directly converted into free amino acid by silver carbonate. Excess of silver was removed as silver sulfide by action of hydrogen sulfide and 4-fluoroglutamic acid 1 was obtained in 83-88% yield based on the fluorinated tetraester derivative 14 (Alekseeva et al., 1967 ) (Scheme 3).
At the same time, Tolman and Veres also independently reported, a similar synthesis of 4-fluoroglutamic acid 1 by electrophilic fluorination of tetraethyl 1-acetamido-1,1,3,3-propanetetracarboxylate 13 with perchloryl fluoride (ClO 3 F) (Tolman and Veres, 1966) . Although the procedure employed by these authors was short and relatively better than the former, the major hurdle was the safety hazards involved in the fluorination step, particularly when the reactions were carried out on a large scale.
• Using 2-chloro-1,1,2-trifluorotriethylamine (CTT): The best way to resolve the hazards involved in the fluorination step was to switch to a safer fluorinating agent. Bergmann and Chun-Hsu synthesised 4-fluoroglutamic acid 1 using CTT-mediated nucleophilic fluorination of an appropriately substituted hydroxyl compound 19. Etherification of ethyl 3-chloro-2-hydroxypropionate 15 with isobutylene afforded the ether derivative 16 which was condensed with diethyl acetamidomalonate 17. The ether group of the adduct 18 was hydrolysed and the deprotected alcohol group was substituted by fluorine using CTT 20. The fluorine derivative 21 was then hydrolysed, decarboxylated and neutralised with silver oxide to give 4-fluoroglutamic acid 1 in 15% overall yield based on 15 (Bergmann and Chun-Hsu, 1973 ) (Scheme 4).
All the existing procedures afforded 4-fluoroglutamic acid 1 as an uncontrolled mixture of stereoisomers. Generally, for biochemical studies, stereochemically pure materials are more informative.
Preparations of enantiomerically enriched 4-fluoroglutamic acid (1a-1d)
Asymmetric syntheses and resolution techniques coupled with enzymatic reactions have been (Dubois et al., 1983) . 1 was prepared using the Michael reaction described above (Buchanan et al., 1962; Hudlicky, 1960 and 1961) and converted into L-leucyl-D,L-(threoϩerythro)-4-fluoroglutamate by coupling with N,O-protected L-leucine (Fig. 3) . The dipeptide mixture was resolved with leucine aminopeptidase into a mixture of L-threo-and L-erythro-4-fluoroglutamates. Ion-exchange chromatography allowed separation of optically pure L-threo-4-fluoroglutamic acid 1b and L-erythro-4-fluoroglutamic acid 1a in 87% ee as determined by HPLC (Bory et al., 1984) .
As L-erythro-4-fluoroglutamic acid 1a was not obtained in high optical purity, an alternative approach was used. The mixture of racemic diastereomers of 4-fluoroglutamic acid 1 was separated into D,L-erythro and D,L-threo-4-fluoroglutamic acid by the ion-exchange method. Chromatographically pure
L-Leucyl-L-erythro-4-fluoroglutamate was isolated by ion-exchange chromatography and hydrolysed by leucine amidopeptidase to give optically pure Lerythro-4-fluoroglutamic acid 1a as shown by HPLC (Fig. 4) (Bory et al., 1984) .
Actually, Unkeless and Goldman previously used this methodology to obtain L-threo-4-fluoroglutamic acid 1b and L-erythro-4-fluoroglutamic acid 1a Goldman, 1970 and 1971) , but the authors did not report the optical rotations and NMR data of the compounds.
With the emergence of this first report on the resolution of 4-fluoroglutamic acid 1, Tolman realized the importance of analytical techniques to determine the sterochemical composition of 4-fluoroglutamic acid 1 samples. The known quantitative cyclization of diethyl 4-fluoroglutamate into a pyrrolidone derivative at high temperature was advantageously exploited to develop an elegant GC method. 4-Fluoroglutamic acid 1 was esterified and injected directly into the injection port at the temperature range of 190 to 230°C allowing separation of erythro and threo isomers on several types of columns (Tolman et al., 1984) . Soon after, Azerad reported gas chromatography resolution of the four stereoisomers as their N-trifluoroacetyl diisopropyl esters (Maurs et al., 1985) .
b) Recrystallisation and aminoacylase resolution:
Kawada et al. also reported the resolution of L-threo and L-erythro-4-fluoroglutamic acid by controlled crystallisation of N-acyl derivatives followed by enzymatic reaction. They claimed that the resolution method is practical and safe for large-scale preparations. The procedure involves the conversion of racemic 4-fluoroglutamic acid 1 to N-chloroacetyl-4-fluoroglutamic acid 5-methyl ester 22, followed by recrystallisation from 2-butanone to afford D,Lerythro enriched (erythro Ͼ99%) 23 and D,L-threo enriched (threo : erythro 94 : 6) 24 diastereomers in 47 and 54% yield, respectively. Subsequent enzymatic resolution of the separated diastereomers using aminoacylase at pH 6.0 gave enantiomerically pure L-isomers in 86% yield after ion-exchange column chromatography (Kokuryo et al., 1996) (Scheme 5). 4-Fluoroglutamic acid 1 was esterified with HCl/ methanol and recrystallised from methanol/ether to give the hydrochloride salt of dimethyl 4-fluoroglutamate enriched in the erythro form (crop 1). Mother liquors were concentrated and crystallised twice from methanol/ether to give a second crop (crop 2) of ester salt derivative enriched in the erythro form. As further treatment of the mother liquors gave the threo isomer in less than 92% optical purity, an alternative effective way was developed.
Thus, the mother liquors were concentrated and subjected to acid hydrolysis to give a mixture of erythro and threo 4-fluoroglutamic acid in approximally 1 : 2 ratio. 4-Fluoroglutamic acid enriched in the threo form was esterified with 2-propanol/HCl and crystallised from acetone to give threo enriched diisopropyl 4-fluoroglutamate salt (crop 3). Mother liquors were concentrated and recrystallized again to give another crop of threo enriched isomer (crop 4). The two crops of erythro (crop 1 and 2) and threo (crop 3 and 4) enriched isomers were individually combined and recrystallised from methanol/ether and acetone, respectively. Finally, the ester derivatives of the erythro and threo isomers were hydrolysed and neutralised with pyridine to afford diastereomerically pure erythro 4-fluoroglutamic acid (1a ϩ 1c) and threo 4-fluoroglutamic acid (1b ϩ 1d) in 54 and 52% overall yield, respectively, based on 1 (Fig. 5) .
Tolman and Simek further pursued the resolution of erythro and threo 4-fluoroglutamic acid into their individual enantiomers by using chiral amines. Thus, erythro-4-fluoroglutamic acid (1a ϩ 1c) was converted into the diastereomeric salts with cinchonine or cinchonidine. The salt of L-erythro acid was crystallised from 50% aqueous dioxane with more than 97% optical purity (crop 1). Mother liquors were concentrated and recrystallised from 50% aqueous dioxane to afford D-erythro acid salt with 88% optical purity (crop 2). Mother liquors were again concentrated and systematically crystallised from 50% aqueous dioxane to give a second crop of L-erythro salt (crop 3) and D-erythro salt (crop 4) with 98% and 95.5% optical purity, respectively. The combined crop of L-erythro salt (crop 1 and 3) and D-erythro salt (crop 2 and 4) were individually released from their chiral auxiliary to afford L-erythro and D-erythro-4-fluoroglutamic acids in 100% and 97.5% optical purity, respectively (Fig. 6) . Overall yields of L-erythro and D-erythro acids were 70.2 and 47%, respectively, based on the presence of these enantiomers in erythro-4-fluoroglutamic acid (1a ϩ 1c) (Tolman and Simek, 2000) .
Attempts to resolve threo-4-fluoroglutamic acid (1b ϩ 1d) in non-derivatised form with chiral amines were unsuccessful. However, this turned out to be possible with quinine by converting threo acid into the N-acetyl derivative.
In an earlier publication, Tolman reported the isolation of enantiomerically pure D-threo-4-fluoroglutamic acid 1d from its racemic threo isomer using brucine as the resolving agent. The overall yield and detailed experimental procedure were not given (Tolman et al., 1985) .
The quinine N-acetyl L-threo-4-fluoroglutamate was obtained with more than 92% optical purity by crystallisation from water. One additional crystallisation enhanced the optical purity to more than 98%. Cationic exchange purification followed by deacetylation under acidic conditions afforded optically pure L-threo acid 1b in 35.7% overall yield based on threo-4-fluoroglutamic acid (1b ϩ 1d) (Fig. 7) . However, processing of the mother liquors obtained from the isolation of the quinine salt of L-threo acid yielded D-threo acid 1d in low yield and optical purity less than 93% (Tolman and Simek, 2000) .
As a result, an enzymatic approach was explored for the preparation of D-threo-4-fluoroglutamic acid 1d. Enzymatic decarboxylation of racemic threo-4-fluoroglutamic acid (1b ϩ 1d) with glutamate decarboxylase gave enantiomerically pure D-threo acid 1d and S-4-amino-2-fluorobutyric acid S-25 in 87 and 83% yield, respectively (Scheme 6). This method was also extended to the preparation of D-erythro isomer 1c (Tolman and Sedmera, 2000) .
The optical purities of the compounds were determined by gas chromatography following chiral separation of the four stereomers of 4-fluoroglutamic acid as their N-(1R,2S,5R)-menthyloxycarbonyl-Omethyl ester derivatives.
Stereoselective synthesis from the chiral pool
The four stereomers of 4-fluoroglutamic acid (1a-1d) have been synthesised using chiral hydroxyprolines and pyroglutaminol as starting materials.
a) Using hydroxyprolines
Hudlicky developed the synthesis of all four stereomers of 4-fluoroglutamic acid (1a-1d) using commercially available trans-4-hydroxy-L-proline 26 and cis-4-hydroxy-D-proline 27.
The authors first prepared L-threo and D-erythro-4-fluoroglutamic acid 1b and 1c from commercially available trans-and cis-4-hydroxyprolines 26 and 27, respectively. The synthetic pathway for 1b involved acetylation of trans-4-hydroxy-L-proline 26, followed by esterification with diazomethane to afford methyl 1-acetyl-trans-4-hydroxy-L-prolinate 28. Fluorination of the latter with diethylaminosulfur trifluoride (DAST) or with 2-chloro-1,1,2-trifluorotriethylamine gave cismethyl 1-acetyl-4-fluoro-L-prolinate 29 in 50% yield, exhibiting conformational isomerism. Rutheniummediated oxidation afforded methyl 1-acetyl-cis-4-fluoro-l-pyrrolidin-5-one-2-carboxylate 30 in 46% yield. Acid hydrolysis of this pyroglutamate derivative gave L-threo-4-fluoroglutamic acid 1b in 18% overall yield based on 26 (Scheme 7). Following the same route, D-erythro-4-fluoroglutamic acid 1c was obtained from cis-4-hydroxy-D-proline 27 in a 13% overall yield Merola, 1990 and .
Conformational isomerism, also observed with the fluoro derivative 31, was later explained by Young using variable temperature 1 H NMR (Avent et al., 1992 ). The authors also described their efforts to develop a stereospecific synthesis of L-threo-4-fluoroglutamic acid 1b using N-tert-butoxycarbonyl-L-pyroglutamate 32 as the chiral starting material. The protected pyroglutamate was stereospecifically converted into the (2S,4R) alcohol 33 in 30% yield, after refining Ohta's procedure (Ohta et al., 1988) . The alcohol was subjected to fluorination with DAST to give cis-4-fluoro derivative 34 in 40% yield (Scheme 8). The authors did not, however, hydrolyse the fluorinated pyroglutamate derivative 34 given the fact that the analogous compound 30 had been previously converted to L-threo-4-fluoroglutamic acid 1b.
Later, Hudlicky extended this strategy to the preparation of D-threo and L-erythro isomers 1d and 1a.
trans-4-Hydroxy-D-proline 36 and cis-4-hydroxy-L-
proline 40, the key intermediates for the synthesis of D-threo and L-erythro isomer were prepared from commercially available cis-4-hydroxy-D-proline 27 and trans-4-hydroxy-L-proline 26, respectively. N-acetylation and diazomethane esterification of cis-4-hydroxy-D-proline 27 gave 35, which under Mitsunobu conditions afforded N-acetyl trans-4-hydroxy-D-proline methyl ester 36 by configuration inversion at carbon 4 of the pyrrolidine ring (Scheme 9). The yield of this reaction was 21-37% (Hudlicky, 1993) . 36 was then converted to D-threo-4-fluoroglutamic acid 1d following the same reaction sequence, reported previously Merola, 1990 and .
For the synthesis of L-erythro-4-fluoroglutamic acid 1a, cis-4-hydroxy-L-proline 40 was prepared from 1-benzyloxycarbonyl-trans-4-hydroxy-L-proline 37 using the oxidation-reduction sequence depicted in Scheme 10. Oxidation with chromium trioxide afforded the 4-keto derivative 38 which on stereospecific reduction with sodium borohydride gave 1-benzyloxycarbonyl-cis-4-hydroxy-L-proline 39. Following deprotection, cis-4-hydroxy-L-proline 40 was obtained in 22% overall yield based on 26. 40 was converted to L-erythro-4-fluoroglutamic acid 1a in a 2% overall yield using the standard protocol (Hudlicky, 1991) .
b) Using pyroglutaminol
Coward and Konas synthesised L-erythro-4-fluoroglutamic acid 1a using L-pyroglutaminol 41 which is commercially available or easily prepared from L-glutamic acid by Pickering's procedure (Pickering et al., 1994) . The key step of the synthesis was the diastereoselective electrophilic fluorination of the pyroglutamic acid derivative 42 with Nfluorobenzenesulphonimide (NFSi), which gave a single isomer of 3-fluoro-protected pyroglutaminol 43 as revealed by 1 H and 19 F NMR analyses of the crude reaction mixture. Complete deprotection of the hydroxyl and amino groups gave the fluorinated pyroglutaminol derivative 44. Oxidation of 44, followed by diazomethane esterification gave the 4-fluoropyroglutamate derivative 45 (Scheme 11). Acid hydrolysis of 45 followed by neutralisation with propylene oxide afforded L-erythro-4-fluoroglutamic acid 1a in 18% overall yield based on 41 (Konas and Coward, 2001 ).
Syntheses of 4-fluoroglutamine 2
The reported chemistry of 4-fluoroglutamine 2 is not as vast as that of 4-fluoroglutamic acid 1. The first synthesis of 4-fluoroglutamic 1 appeared in 1960 and it was only three years later that the first report on the synthesis of 2 appeared in the literature. To date, the only synthetic route to 4-fluoroglutamine obtained as a mixture of stereoisomers and as a diastereomeric racemate of erythro and threo forms starts from the corresponding 4-fluoroglutamic acid.
Preparation of 4-fluoroglutamine 2 as a mixture of stereoisomers
In an early synthesis, Tolman prepared 4-fluoroglutamine 2 by regioselective esterification of the γ-carboxyl group followed by aminolysis. The γ-carboxyl group of 4-fluoroglutamic acid 1 was esterified with methanolic hydrochloric acid in 41.5% yield. The aminolysis of the resulting γ-ester derivative 46 by ammonia in the presence of carbon disulfide as α-amino protecting group gave 4-fluoroglutamine 2 in only 28% yield (Tolman, 1964) (Scheme 12). Later, Tolman and Veres improved the overall yield of 4-fluoroglutamine 2 using basically the same synthetic path, but slightly different conditions. In the revised procedure, 1 was esterified with methanol in the presence of thionyl chloride to afford γ-methyl ester derivative 46 in 58% yield. Aminolysis of the ester with methanolic ammonia in the presence of carbon disulfide afforded 4-fluoroglutamine 2 in 36% yield (Tolman and Veres, 1967) . The importance of amino group protection of the γ-ester derivative of 4-fluoroglutamic acid was recognised when aminolysis of the monoester of 4-fluoroglutamic acid 46 gave a mixture of cis and trans-4-fluoro-5-pyrrolidone-2-carboxylic acids ).
Preparation of diastereomeric 4-fluoroglutamine (2a ϩ 2c & 2b ϩ 2d)
After their successful separation of erythro and threo-4-fluoroglutamic acid (Tolman, 1993; Tolman et al., 1993) , Tolman and Sedmera converted them to the corresponding diastereomeric 4-fluoroglutamine. Racemic erythro and threo-4-fluoroglutamic acid were individually converted into their 5-methyl ester hydrochloride salt with thionyl chloride and methanol. Temporary protection of the amino group as the tertbutyloxycarbonyl derivative 47 followed by aminolysis with 28% aqueous ammonia gave N-protected 4-fluoroglutamine. Release of the protecting group with TFA gave erythro-4-fluoroglutamine (2a ϩ 2c) and threo-4-fluoroglutamine (2b ϩ 2d) in 35% and 39% overall yields based on the corresponding diastereomeric erythro and threo-4-fluoroglutamic acid, respectively (Tolman and Sedmera, 2000) (Scheme 13).
It is worth noting that the same transformations have not yet been applied to the synthesis of enantiomerically pure 4-fluoroglutamine (2a-2d) despite the available procedures for the preparation of all four stereomers of 4-fluoroglutamic acid (1a-1d).
Syntheses of 4,4-difluoroglutamic acid 48 and 4,4-difluoroglutamine 49
Replacement of the two γ-hydrogens of glutamic acid and glutamine with fluorine atoms gives the corresponding 4,4-difluoroglutamic acid 48 and 4,4-difluoroglutamine 49, respectively, in the two possible enantiomeric forms.
4,4-Difluoroglutamic acid 48
The chemistry of 4,4-difluoroglutamic acid 48 evolved very late compared to γ-fluoroglutamic acid 1. 4,4-Difluoroglutamic acid 48 was prepared in racemic form by nitroaldol reaction and in optically active form by asymmetric syntheses using either a chiral acryloxazolidinone derivative, an L-pyroglutaminol or an L-serine aldehyde equivalent as chiral building blocks.
Syntheses of D,L-4,4-difluoroglutamic acid 48
After synthesising and investigating the FPGS substrate properties of 4-fluoroglutamic acid, and 3,3-difluoroglutamic acid as glutamate surrogates (Licato et al., 1990; Hart et al., 1996) , Coward and co-workers switched to the synthesis of racemic D,L-4,4-difluoroglutamic acid 48 to explore similar biological properties. The authors also realized that 4,4-difluoroglutamic acid 48 could prove useful for the preparation of the MTX analogue, 4,4-F2MTX, to investigate the biochemical reactions catalyzed by folate-dependent enzymes and its effects on cell growth.
Ethyl nitroacetate 50 was subjected to nitroaldol reaction with the difluorinated hemiacetal 51 to give the nitro alcohol adduct 52 which after acetylation and subsequent deoxygenation afforded 53. This chromatographically pure product underwent hydrogenation on Raney nickel followed by acid hydrolysis and anion-exchange purification to give D,L-4,4-difluoroglutamic acid D,L-48 in 37% overall yield based on 51 (Scheme 14) . D,L-48 slightly inhibited the FPGS-catalysed reaction suggesting that it was either a poor alternate substrate or a weak reversible inhibitor of FPGS. In fact, although D,L-48 is less reactive than Glu, it indeed serves as an alternate substrate for FPGScatalysed polyglutamylation. In other biological studies, D,L-4,4-difluoroglutamic acid D,L-48 was converted to 4,4-F2MTX employing the Piper and Montgomery procedure (Piper and Montgomery, 1977) . By comparison with the substrate behaviour of MTX, it was found that 4,4-F2MTX binds poorly to FPGS and is neither a substrate nor an inhibitor of FPGS. (Tsushima et al., 1988) . They extended the Michael addition of 2,2-difluoroketene silyl acetal 55 to α, -unsaturated carbonyl compounds or acetals for asymmetric synthesis of L-4,4-difluoroglutamic acid L-48. The key substrate in the methodology, 2,2-difluoroketene silyl acetal 55, was generated in situ by reaction of methyl difluoroiodoacetate 54 with zinc and triethylchlorosilane. 1,4-Addition of 55 to Racryloxazolidinone derivative 56 gave 57 in 40% yield. NBS-bromination of the Z-boron enolate (resulting from dibutylboron triflate/DIEA treatment of 57) followed by azide displacement of the resulting bromide derivative 58 (2R/2S ϭ 8.6) gave 59 in 64% yield. Hydrolysis of the ester and imide groups of the major 2S-isomer of 59 and subsequent hydrogenation afforded L-4,4-difluoroglutamic acid L-48 in 74% yield (Scheme 15). Using the same reaction sequence, D-4,4-difluoroglutamic acid D-48 was prepared from the (S)-enantiomer of acryloyloxazolidinone derivative for optical purity determination. Both enantiomers of 4,4-difluoroglutamic acid were optically pure as revealed by 1 H NMR of the (S)-MTPA-Mosher's amides of their dimethyl ester derivatives (Kitagawa et al., 1990 , Kobayashi et al., 1991 . (Pickering et al., 1994) ). Amino acetalisation of 41 with DMP gave the bicyclic lactam 60. Two-step electrophilic fluorination of the lactam 60 with NSFi gave successively mono then difluorinated product 61, which was cleaved with acetic acid in aqueous acetonitrile to yield L-difluoropyroglutaminol 62. Jones oxidation of 62 gave the difluoropyroglutamate carboxylate intermediate which on acid hydrolysis followed by neutralisation and crystallisation provided L-4,4-difluoroglutamic acid L-48 in 12% overall yield based on 41 Coward, 1999 and (Scheme 16).
c) Reformatsky reaction. Richards synthesised L-4,4-difluoroglutamic acid L-48 using the configurationally stable L-serine aldehyde equivalent 64 as the chiral building block, which was prepared from N-protected L-serine 63 using Lajoie's procedure (Blaskovich et al., 1998) . Reformatsky reaction of ethyl bromodifluoroacetate with aldehyde 64 gave a mixture of anti : syn (7 : 1) alcohol derivative 65. The latter diastereomeric mixture was thiocarbonylated before radical-promoted deoxygenation to afford the protected L-4,4-difluoroglutamic acid 66. Acid hydrolysis of the deoxygenated product 66 followed by anion exchange chromatography gave optically pure L-4,4-difluoroglutamic acid L-48 in 44% overall yield based on 64 (Scheme 17). Optical purity was determined by comparison with the reported specific rotation values (Ding et al., 2001) .
4,4-Difluoroglutamine 49
The conversion of racemic 4,4-difluoroglutamic acid 48 into the corresponding 4,4-difluoroglutamine 49 was accomplished only during the last decade. Two syntheses of 4,4-difluoroglutamine 49 have been reported so far: the first is racemic while the second is in the L series.
Synthesis of D,L-4,4-difluoroglutamine 49
Coward and Tsukamoto converted D,L-4,4-difluoroglutamic acid 48 into the N-protected benzyloxycarbonyl derivative 67 which was esterified with isobutylene to give the fully protected acid derivative 68. The enhanced electrophilic character of the γ-carbonyl in 68 which is due to the two adjacent fluorine atoms resulted in the regioselective aminolysis of the γ-carboxyl ester. Routine deprotection of amino and carboxyl groups of the amide derivative 69 yielded D,L-difluoroglutamine 49 in 29% overall yield based on 48 (Garner and Park, 1992; Meffre et al., 1994) was subjected to Reformatsky reaction using ethyl bromodifluoroacetate. Thiocarbonylation of the resulting diastereomeric mixture of alcohol derivative 72 (d.r. ϭ 7 : 1) with TCDI followed by Barton-McCombie radical reaction gave the deoxygenated derivative 73. Periodic acid oxidation of 73 in the presence of catalytic chromium trioxide gave the L-4,4-difluoroglutamic acid derivative 74. Aminolysis of 74 with aqueous ammonia gave N-Boc-L-4,4-difluoroglutamine 75 in 24% overall yield based on 74 (Meffre et al., 2001 ) (Scheme 19). The optical purity of 75 was found to be Ͼ99% as deduced from chiral HPLC analysis.
Acid hydrolysis of the Boc protecting group of 75 resulted in isolation of a pure compound which exhibited spectroscopic properties compatible with L-4,4-difluoroglutamine L-49. Unfortunately, both microanalysis and electrospray mass spectroscopy analysis in negative mode indicated that deprotection resulted actually in the simultaneous cleavage of the amide group to give L-4,4-difluoroglutamic acid L-48 (Meffre et al., 2002) . The facile hydrolytic cleavage of the amide group, which was not noticed in the synthesis of D,L-4,4-difluoroglutamine D,L-49, likely results from the strong electronegativity of the two adjacent fluorine atoms. This problem might be circumvented using other amino protecting groups, which could be cleaved under non-hydrolytic conditions. But before L-4,4-difluoroglutamine L-49 can be prepared and used for biological studies, a number of questions regarding the stability of this compound must be answered.
Concluding remarks
4-Fluoroglutamic acid 1 has attracted the attention of biochemists because of its antimetabolic properties (Tolman and Veres, 1966; Drsata et al., 1999 and . Its use as an alternative substrate to lead to a fluorinated analogue of the antitumor agent methotrexate emphasised the possibilities of obtaining clinically more potent analogues, particularly to treat patients developing drug resistance (Licato et al., 1990) .
4-Fluoroglutamic acid 1 as a mixture of racemic diastereomers was prepared by different methodologies, the original method using a Michael reaction developed by Hudlicky and optimized by Tolman being more practical and elegant for large scale preparations. 4-Fluoroglutamic acids (1a-1d) of different optical purities can be obtained via various resolution techniques such as preferential crystallisation or ion-exchange chromatography coupled with enzymatic separation. As resolution methods demand time and patience for optimisation, chemists generally prefer the asymmetric synthesis approach. Asymmetric syntheses for preparation of all four stereoisomers were reported using commercially available hydroxyprolines and pyroglutaminol. The overall yield of enantiomerically pure 4-fluoroglutamic acid is at best 18%. There is then obviously a need for improved access to optically pure 4-fluoroglutamic acid 1. The extremely high costs of L-erythro, Derythro and D-threo-4-fluoroglutamic acids (1a, 1c & 1d) should stimulate research in that direction.
As a corollary, there is also keen interest in the syntheses of γ-fluorinated glutamines, for example, in order to investigate whether the Gn-AT could employ this unnatural amino acid as a nitrogen source in place of glutamine. These fluorinated glutamine analogues might help to trap and structurally characterise specific intermediates formed during the amide nitrogen transfer.
4-Fluoroglutamine 2 was prepared as a mixture of stereoisomers and as diastereomeric erythro and threo forms from the corresponding 4-fluoroglutamic acid using conventional protection / aminolysis / deprotection approaches. In spite of the fact that all four stereoisomers of 4-fluoroglutamic acid (1a-1d) have been prepared, none of them has been converted into the corresponding enantiomerically pure 4-fluoroglutamine (2a-2d). L-erythro-4-fluoroglutamine 2a which is not described in the literature is nevertheless commercially available, though very expensive.
Racemic 4,4-difluoroglutamic acid D,L-48 was prepared by nitroaldol reaction while its L-enantiomer could be prepared by Michael addition of 2,2-difluoroketene silyl acetal 55 to (R)-acryloyloxazolidinone 56 or by electrophilic fluorination of appropriately substituted enantiomeric lactam 60. A recent method reported by Richards involving Lserine equivalent aldehyde 64 as a chiral building block seems to be a more promising approach for preparing L-4,4-difluoroglutamic L-48.
Racemic 4,4-difluoroglutamic acid D,L-48 was converted to the corresponding glutamine D,L-49 using the amino protection, aminolysis and subsequent deprotection strategy. L-4,4-Difluoroglutamine L-49 as the N-Boc derivative 75 is obtained in an elegant way directly from (R)-Garner's aldehyde 71 using the Reformatsky reaction as a key step.
As mentioned above, hydrolytic cleavage of N-Boc protecting group did not lead to L-4,4-difluoroglutamine L-49 but to L-4,4-difluoroglutamic acid L-48. The high sensitivity of the amide bond of L-49 to hydrolytic conditions likely explains the lack of data concerning its biological applications despite a strong reported interest in this glutamine analogue.
As reported in literature, the chemical reactivity of these biologically important compounds changes significantly due to the presence of adjacent fluorine atoms. Therefore, there is still a strong demand for efficient enantio and diastereoselective syntheses of γ-fluorinated derivatives of glutamic acid and glutamine as well as other fluorinated analogues. There is little doubt that that these compounds will find interesting biochemical and pharmacological applications in the future.
